Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG TEMPO PEN versus NOVOLOG INNOLET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG TEMPO PEN versus NOVOLOG INNOLET.
HUMALOG TEMPO PEN vs NOVOLOG INNOLET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially in skeletal muscle and fat, and by inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase and downstream signaling pathways.
Insulin aspart is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase activity, which leads to glucose transporter translocation and metabolic effects.
Subcutaneously, 0.2-0.5 units/kg within 15 minutes before or after a meal. Total daily dose is 0.5-1.0 units/kg.
Subcutaneous injection, 0.5-1.0 unit/kg/day in divided doses, with meals.
None Documented
None Documented
1.0 hour (terminal elimination half-life); reflects rapid clearance of insulin lispro from circulation.
Terminal half-life: 81 minutes (range 70–90 minutes) for subcutaneous administration; reflects absorption-rate limited elimination
Renal: 100% of absorbed dose is eliminated via degradation, primarily in the liver and kidneys; no significant biliary/fecal excretion.
Renal: approximately 30% of total clearance as unchanged drug; hepatobiliary/fecal: minor (less than 1%)
Category C
Category C
Insulin Analog
Insulin Analog